IP Library › Granted Patent US 12,501,893
Granted Patent B2
US 12,501,893 · App. 14/972,535 · Granted Dec 23, 2025

Method and composition for hypothermic storage of placental tissue

Inventors: Howard P. Walthall, Jr. (Birmingham, AL); Katie C. Mowry (Gardendale, AL); Jeremy B. Vines (Birmingham, AL)
Assignee: Prime Merger Sub, LLC
A01N1/126A01N1/142A01N1/146A61K35/50C12N5/0605
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,501,893
App. No.
14/972,535
Granted
Dec 23, 2025
Kind
B2
Abstract

A tissue storage solution includes hypothermic storage compositions and methods. The hypothermic storage composition includes media containing Dulbecco's modified Eagle's medium (DMEM) and albumin. A method of hypothermically storing tissue includes storing such tissue in a storage medium including DMEM and albumin. A method for wound or defect treatment includes applying tissue, stored in a hypothermic storage medium containing DMEM and albumin, to the site of such wound or defect.

Claims (11)

1 . A tissue comprising a placental membrane exhibiting a cell viability range of 45% to 85% following one thousand hours of being stored at a temperature from 0° C. to 20° C. in a solution comprising Dulbecco's modified Eagle's medium (DMEM) and human plasma albumin, wherein the placental membrane is a meshed placental membrane, wherein the length and width of the placental membrane is increased as a result of the meshing, wherein the placental membrane is at least partially submerged in the solution, and wherein the placental membrane has a protein content of about 100 ng to 500 ng of protein per mg of the placental membrane.

2 . The tissue according to claim 1 wherein the solution comprises 2.5 g/L 0.025% w/v human plasma albumin.

3 . The tissue according to 1 , claim wherein the placental membrane exhibits a ratio of live cells to dead cells of about 1.0.

4 . The tissue according to claim 1 , wherein the placental membrane has a protein content of about 300 ng of protein per mg of the placental membrane.

5 . The tissue according to claim 1 , wherein the placental membrane has a tissue inhibitor of matrix metalloproteinases 1, 2 and 4 protein content of more than 250 ng of protein per mg of the placental membrane following one-thousand hours of being stored at a temperature from 0° C. to 20° C. in the solution.

6 . The tissue according to claim 1 , wherein the placental membrane is stored at a temperature from 0° C. to 20° C. between nested trays.

7 . The tissue according to claim 1 , comprising cartilage.

8 . The tissue according to claim 1 , wherein the placental membrane is not frozen prior to, during or after being stored at a temperature from 0° C. to 20° C. in the solution.

9 . The tissue according to claim 1 , wherein the placental membrane includes an amnion.

10 . The tissue according to claim 1 , wherein the placental membrane includes a chorion.

11 . The tissue according to claim 1 , wherein the placental membrane excludes a chorion.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Aug 12, 2026
From: FIRST-CITIZENS BANK & TRUST COMPANY
To: PRIME MERGER SUB, LLC
Reel/Frame 075619/0612 →
SECURITY INTEREST Recorded Aug 6, 2021
From: ORGANOGENESIS INC.; PRIME MERGER SUB, LLC
To: SILICON VALLEY BANK
Reel/Frame 057108/0846 →
TERMINATION AND RELEASE OF PATENT SECURITY AGREEMENT Recorded Aug 6, 2021
From: PRIME MERGER SUB, LLC
To: SILICON VALLEY BANK
Reel/Frame 057112/0703 →
MERGER AND CHANGE OF NAME Recorded Apr 11, 2019
From: NUTECH MEDICAL, INC.; PRIME MERGER SUB, LLC
To: PRIME MERGER SUB, LLC
Reel/Frame 048860/0093 →
SECURITY INTEREST Recorded Jun 19, 2018
From: PRIME MERGER SUB, LLC
To: SILICON VALLEY BANK
Reel/Frame 046131/0325 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 14, 2018
From: WALTHALL, HOWARD P., JR.; MOWRY, KATIE C.; VINES, JEREMY B.
To: NUTECH MEDICAL, INC.
Reel/Frame 045204/0012 →
SECURITY INTEREST Recorded Mar 28, 2017
From: PRIME MERGER SUB, LLC
To: SILICON VALLEY BANK
Reel/Frame 041767/0804 →
Continuity (2)
Division 14508398 · Oct 7, 2014
Related Publication 20160100571A1 · Apr 14, 2016
References Cited (40)
US 6152142A · Tseng · 2000 [cited by applicant]
US 6326019B1 · Tseng · 2001 [cited by applicant]
US 6548297B1 · Kuri-Harcuch et al. · 2003 [cited by applicant]
US 7488348B2 · Truncale · 2009 [cited by examiner]
US 8071135B2 · Liu et al. · 2011 [cited by applicant]
US 8338175B2 · Devi et al. · 2012 [cited by applicant]
US 8354221B2 · Roy et al. · 2013 [cited by applicant]
US 8375688B2 · Ishihara et al. · 2013 [cited by applicant]
US 8460650B2 · Edinger et al. · 2013 [cited by applicant]
US 9433490B2 · McFetridge · 2016 [cited by examiner]
US 20030187515A1 · Hariri et al. · 2003 [cited by applicant]
US 20030235580A1 · Zhang et al. · 2003 [cited by applicant]
US 20040048372A1 · Hariri · 2004 [cited by applicant]
US 20100228335A1 · Schorgl · 2010 [cited by examiner]
US 20110206776A1 · Tom · 2011 [cited by examiner]
US 20110281352A1 · Raeder et al. · 2011 [cited by applicant]
US 20120207717A1 · Sing · 2012 [cited by applicant]
US 20130071363A1 · Smith et al. · 2013 [cited by applicant]
US 20130084314A1 · Horton · 2013 [cited by examiner]
US 20130136773A1 · Horton et al. · 2013 [cited by applicant]
US 20130195806A1 · Gay et al. · 2013 [cited by applicant]
US 20130252226A1 · Schweizer · 2013 [cited by applicant]
US 20130344163A1 · Tseng et al. · 2013 [cited by applicant]
US 20140011743A1 · Bhatia et al. · 2014 [cited by applicant]
US 20140017193A1 · Sing et al. · 2014 [cited by applicant]
US 20140212390A1 · Tabet, Jr. et al. · 2014 [cited by applicant]
CN 102763639 · 2012 [cited by applicant]
CN 20130344163 · 2013 [cited by applicant]
CN 103789262A1 · 2014 [cited by applicant]
WO 2009120996A1 · 2009 [cited by applicant]
WO 2014057220A1 · 2014 [cited by applicant]
WO 2015171143A1 · 2015 [cited by applicant]
WO 2015171144A1 · 2015 [cited by applicant]
Krisnamurthy et al. “Human amniotic membrane as a chondrocyte carrier vehicle/substrate: In vitro study” 2011, J Biomed Mater Res Part A, vol. 99A: 500-506. [cited by examiner]
Adds, Philip J., et al.; Amniotic Membrane Grafts, “Fresh” or Frozen? A Clinical and In Vitro Comparison; Br F Ophthalmol 2001, 85, pp. 905-907. [cited by applicant]
Xu L., et al.; A Study on the Preservation of Fresh Amniotic Membrane; Yan Ke Xue Bao, Sep. 17, 2001 (3); 158-162. [cited by applicant]
Hennerbichler Simone, et al.; The Influence of Various Storage Conditions on Cell Viability in Amniotic Membrane; Cell Tissue Banking (2007) 8:1-8. [cited by applicant]
Arora, “Cell Culture Media: A Review” (2013) Mater Methods, vol. 3, No. 175:1-33. [cited by applicant]
Brockbank K & Taylor MJ. “Tissue Preservation” Advances in Biopreservation, Ch 8, 2006, pp. 159-165. [cited by applicant]
Hussin et al. “The Fabrication of Human Amniotic Membrane Based Hydrogel for Cartilage Tissue Engineering Applications: A Preliminary Study” Biomed 2011, IFMBE Proceedings 35, pp. 841-844. [cited by applicant]